Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.

@article{Hoellein2014MycinducedSI,
  title={Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.},
  author={Alexander Hoellein and Mohammad Fallahi and Stephanie Schoeffmann and Sabine Steidle and Franz X. Schaub and Martina Rudelius and Iina E K Laitinen and Lisa M. Nilsson and Andrei Goga and Christian Peschel and Jonas Nilsson and John L. Cleveland and Ulrich Keller},
  journal={Blood},
  year={2014},
  volume={124 13},
  pages={2081-90}
}
Myc oncogenic transcription factors (c-Myc, N-Myc, and L-Myc) coordinate the control of cell growth, division, and metabolism. In cancer, Myc overexpression is often associated with aggressive disease, which is in part due to the destruction of select targets by the ubiquitin-proteasome system (eg, SCF(Skp2)-directed destruction of the Cdk inhibitor p27(Kip1)). We reasoned that Myc would also regulate SUMOylation, a related means of posttranslational modification of proteins, and that this… CONTINUE READING